Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan.
Seiko BunKan YonemoriHiroko SunadoiRena NishigakiEmi NoguchiTakuji OkusakaToshirou NishidaYasuhiro FujiwaraPublished in: JCO oncology practice (2020)
As reported in previous studies, pharmaceutical products were generally used off-label for the treatment of rare cancers, for which large-scale clinical trials are difficult to conduct. Continued discussion of the types of frameworks that are needed to guide pharmaceutical development is necessary.